Innovstone Therapeutics Ltd. has described aromatic heterocyclic compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors potentially useful for the treatment of pancreatic cancer, heart failure and myocardial infarction.